FDA officials argue over safety of new arthritis drug.

Ray Moynihan

doi:10.1136/bmj.326.7389.565/a

FDA officials argue over safety of new arthritis drug.

Ray Moynihan^*

^*Corresponding author for this work

Institute for Evidence-Based Healthcare

Research output: Contribution to journal › Article › Professional

5 Citations (Scopus)

Abstract

An external advisory panel to the US Food and Drug Administration last week rejected calls from FDA safety experts to withdraw a drug for rheumatoid arthritis from the market.

Original language	English
Pages (from-to)	565-565
Number of pages	1
Journal	BMJ (Clinical research ed.)
Volume	326
Issue number	7389
DOIs	https://doi.org/10.1136/bmj.326.7389.565/a
Publication status	Published - 15 Mar 2003

Access to Document

10.1136/bmj.326.7389.565/a

Cite this

@article{25a8411d687940ed9e7be3474c7ee700,

title = "FDA officials argue over safety of new arthritis drug.",

abstract = "An external advisory panel to the US Food and Drug Administration last week rejected calls from FDA safety experts to withdraw a drug for rheumatoid arthritis from the market.",

author = "Ray Moynihan",

year = "2003",

month = mar,

day = "15",

doi = "10.1136/bmj.326.7389.565/a",

language = "English",

volume = "326",

pages = "565--565",

journal = "BMJ (Clinical research ed.)",

issn = "0959-535X",

publisher = "BMJ Publishing Group",

number = "7389",

}

TY - JOUR

T1 - FDA officials argue over safety of new arthritis drug.

AU - Moynihan, Ray

PY - 2003/3/15

Y1 - 2003/3/15

N2 - An external advisory panel to the US Food and Drug Administration last week rejected calls from FDA safety experts to withdraw a drug for rheumatoid arthritis from the market.

AB - An external advisory panel to the US Food and Drug Administration last week rejected calls from FDA safety experts to withdraw a drug for rheumatoid arthritis from the market.

UR - https://www.scopus.com/pages/publications/0037445259

U2 - 10.1136/bmj.326.7389.565/a

DO - 10.1136/bmj.326.7389.565/a

M3 - Article

C2 - 12637379

AN - SCOPUS:0037445259

SN - 0959-535X

VL - 326

SP - 565

EP - 565

JO - BMJ (Clinical research ed.)

JF - BMJ (Clinical research ed.)

IS - 7389

ER -

FDA officials argue over safety of new arthritis drug.

Abstract

Access to Document

Other files and links

Fingerprint

Cite this